Cargando…
Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
A third of patients with non-small cell lung cancer (NSCLC) present with un-resectable stage III locally advanced disease and are currently treated by chemo-radiotherapy but the median survival is only about 21 months. Using an orthotopic xenograft model of lung carcinoma, we have investigated the c...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145357/ https://www.ncbi.nlm.nih.gov/pubmed/24862536 http://dx.doi.org/10.1016/j.tranon.2014.04.002 |